Proteomic Signature of Subclinical Coronary Artery Disease in People with HIV: Analysis of the REPRIEVE Mechanistic Substudy

By rosaguerrero • May 11, 2022

Kolossváry M, deFilippi C, Lu MT, Zanni MV, Fulda ES, Foldyna B, Ribaudo H, Mayrhofer T, Collier AC, Bloomfield GS, Fichtenbaum C, Overton ET, Aberg JA, Currier J, Fitch KV, Douglas PS, Grinspoon SK. Proteomic Signature of Subclinical Coronary Artery Disease in People with HIV: Analysis of the REPRIEVE Mechanistic Substudy. J Infect Dis. 2022 May 10:jiac196. doi: 10.1093/infdis/jiac196. Epub ahead of print. PMID: 35535576.

Tags: coronary artery disease, CTA, HIV, Infectious Diseases, plaque, proteomics, Publications

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]

Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024

Caldera JR, Shaw B, Uslan DZ, Yang S. Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024. Am J Infect Control. 2024[...]

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa[...]